ArticleThe pharmacogenomics journal2024

TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer.

Xiaolin Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.